Sputum proteomics in lung disorders.

Asthma Biomarker COVID-19 Chronic obstructive pulmonary disease Cystic fibrosis Lung cancer Mass spectrometry Proteomics Sputum Tuberculosis

Journal

Advances in clinical chemistry
ISSN: 2162-9471
Titre abrégé: Adv Clin Chem
Pays: United States
ID NLM: 2985173R

Informations de publication

Date de publication:
2024
Historique:
medline: 8 8 2024
pubmed: 8 8 2024
entrez: 7 8 2024
Statut: ppublish

Résumé

Lung diseases affect pulmonary and respiratory function and are caused by bacterial viral and fungal infection as well as environmental factors. Unfortunately, symptom overlap between various pulmonary diseases often prevents clear differentiation and uncertain diagnosis. Accordingly, identification of specific markers of inflammatory activity in early disease stage could potential unveil the intrinsic molecular mechanisms of the underlying pathology. Proteomic studies aimed at understanding the genetic/environmental contributions to the development and progression of lung diseases represent a promising approach for diagnosis and treatment. The fluid phase of sputum represents a rich protein source and is frequently used in these studies. This chapter addresses causes of lung disorders, sputum composition, collection and processing as well as the clinical significance and challenges associated with the presence of interfering factors. Basics of proteomics and mass spectrometry are also described, together with the analytical approaches to investigate the sputum proteome. Finally, we explore the application of sputum proteomics in severe lung disorders including COVID-19 infection, chronic obstructive pulmonary disease, asthma, cystic fibrosis, lung cancer and tuberculosis.

Identifiants

pubmed: 39111963
pii: S0065-2423(24)00093-3
doi: 10.1016/bs.acc.2024.06.002
pii:
doi:

Substances chimiques

Biomarkers 0
Proteome 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

171-208

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Auteurs

Paolo Iadarola (P)

Department of Biology and Biotechnologies "L. Spallanzani", University of Pavia, Pavia, Italy. Electronic address: paolo.iadarola@unipv.it.

Maura D'Amato (M)

Department of Molecular Medicine, University of Pavia, Pavia, Italy.

Maria Antonietta Grignano (MA)

Unit of Nephrology, Dialysis and Transplantation, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.

Simona Viglio (S)

Department of Molecular Medicine, University of Pavia, Pavia, Italy; Lung Transplantation Unit, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH